RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $18.17 Consensus PT from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned an average recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $18.17.

Several brokerages recently issued reports on RAPT. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th. UBS Group lowered their target price on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a report on Monday, September 9th.

Institutional Trading of RAPT Therapeutics

Several institutional investors have recently modified their holdings of RAPT. China Universal Asset Management Co. Ltd. raised its position in shares of RAPT Therapeutics by 65.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,602 shares of the company’s stock worth $59,000 after purchasing an additional 2,621 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of RAPT Therapeutics by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after acquiring an additional 3,824 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of RAPT Therapeutics in the first quarter valued at approximately $97,000. Charles Schwab Investment Management Inc. boosted its stake in shares of RAPT Therapeutics by 5.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 234,439 shares of the company’s stock worth $5,826,000 after acquiring an additional 12,650 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in shares of RAPT Therapeutics during the first quarter worth approximately $161,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Price Performance

Shares of NASDAQ RAPT opened at $2.01 on Thursday. RAPT Therapeutics has a 1-year low of $1.73 and a 1-year high of $27.35. The business’s 50 day moving average is $2.31 and its two-hundred day moving average is $4.45. The stock has a market capitalization of $70.15 million, a P/E ratio of -0.65 and a beta of 0.33.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.03. As a group, equities research analysts anticipate that RAPT Therapeutics will post -2.73 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.